论文部分内容阅读
目的:观察升白散治疗化疗所致白细胞减少的临床疗效。方法:将72例化疗患者随机分成2组,治疗组36例,化疗前1天开始服中药到化疗结束后第2天停服;对照组36例,仅进行常规化疗,不服中药。结果:化疗后白细胸减少发生率治疗组为27.8%,对照组为63.8%,两组比较,差异有统计学意义(P<0.05);胃肠道反应发生率治疗组为69.4%,对照组为94.4%,两组比较,差异有统计学意义(P<0.01)。结论:升白散治疗化疗所致白细胞减少症,疗效满意。
Objective: To observe the clinical efficacy of Shengbai San on chemotherapy-induced leukopenia. Methods: 72 cases of chemotherapy were randomly divided into two groups, the treatment group of 36 cases, one day before chemotherapy began to take traditional Chinese medicine to the end of chemotherapy after 2 days to stop taking; control group of 36 patients, only routine chemotherapy, not to accept traditional Chinese medicine. Results: The incidence of white chest reduction after chemotherapy was 27.8% in the treatment group and 63.8% in the control group, with significant difference between the two groups (P <0.05). The incidence of gastrointestinal reactions in the treatment group was 69.4% Group was 94.4%, the difference between the two groups was statistically significant (P <0.01). Conclusion: Shengbai San chemotherapy-induced leukopenia, with satisfactory results.